Literature DB >> 10079068

Influence of amino acid substitutions related to inherited human prion diseases on the thermodynamic stability of the cellular prion protein.

S Liemann1, R Glockshuber.   

Abstract

Transmissible spongiform encephalopathies (TSEs) are caused by a unique infectious agent which appears to be identical with PrPSc, an oligomeric, misfolded isoform of the cellular prion protein, PrPC. All inherited forms of human TSEs, i.e., familial Creutzfeldt-Jakob disease, Gerstmann-Sträussler-Scheinker syndrome, and fatal familial insomnia, segregate with specific point mutations or insertions in the gene coding for human PrP. Here we have tested the hypothesis that these mutations destabilize PrPC and thus facilitate its conversion into PrPSc. Eight of the disease-specific amino acid replacements are located in the C-terminal domain of PrPC, PrP(121-231), which constitutes the only part of PrPC with a defined tertiary structure. Introduction of all these replacements into PrP(121-231) yielded variants with the same spectroscopic characteristics as wild-type PrP(121-231) and similar to full-length PrP(23-231), which excludes the possibility that the exchanges a priori induce a PrPSc-like conformation. The thermodynamic stabilities of the variants do not correlate with specific disease phenotypes. Five of the amino acid replacements destabilize PrP(121-231), but the other variants have the same stability as the wild-type protein. These data suggest that destabilization of PrPC is neither a general mechanism underlying the formation of PrPSc nor the basis of disease phenotypes in inherited human TSEs.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10079068     DOI: 10.1021/bi982714g

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  76 in total

1.  Conformational propagation with prion-like characteristics in a simple model of protein folding.

Authors:  P M Harrison; H S Chan; S B Prusiner; F E Cohen
Journal:  Protein Sci       Date:  2001-04       Impact factor: 6.725

2.  Protein engineering as a strategy to avoid formation of amyloid fibrils.

Authors:  V Villegas; J Zurdo; V V Filimonov; F X Avilés; C M Dobson; L Serrano
Journal:  Protein Sci       Date:  2000-09       Impact factor: 6.725

Review 3.  The molecular pathology of CJD: old and new variants.

Authors:  G S Jackson; J Collinge
Journal:  Mol Pathol       Date:  2001-12

4.  The role of dimerization in prion replication.

Authors:  Peter Tompa; Gábor E Tusnády; Peter Friedrich; István Simon
Journal:  Biophys J       Date:  2002-04       Impact factor: 4.033

5.  Computational studies on prion proteins: effect of Ala(117)-->Val mutation.

Authors:  Noriaki Okimoto; Kazunori Yamanaka; Atsushi Suenaga; Masayuki Hata; Tyuji Hoshino
Journal:  Biophys J       Date:  2002-05       Impact factor: 4.033

Review 6.  Protein aggregation in disease: a role for folding intermediates forming specific multimeric interactions.

Authors:  Arthur Horwich
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

7.  Multiple substitutions of methionine 129 in human prion protein reveal its importance in the amyloid fibrillation pathway.

Authors:  Sofie Nyström; Rajesh Mishra; Simone Hornemann; Adriano Aguzzi; K Peter R Nilsson; Per Hammarström
Journal:  J Biol Chem       Date:  2012-06-05       Impact factor: 5.157

8.  Sequence determinants of amyloid fibril formation.

Authors:  Manuela López de la Paz; Luis Serrano
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-22       Impact factor: 11.205

9.  Autocatalytic self-propagation of misfolded prion protein.

Authors:  Jan Bieschke; Petra Weber; Nikolaus Sarafoff; Michael Beekes; Armin Giese; Hans Kretzschmar
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-05       Impact factor: 11.205

10.  Exploring amyloid formation by a de novo design.

Authors:  Richard A Kammerer; Dirk Kostrewa; Jesús Zurdo; Andreas Detken; Carlos García-Echeverría; Janelle D Green; Shirley A Müller; Beat H Meier; Fritz K Winkler; Christopher M Dobson; Michel O Steinmetz
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-26       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.